These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 3124536

  • 61. B cell suppression in primary glomerular disease.
    Rood IM, Hofstra JM, Deegens JK, Wetzels JF.
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):166-81. PubMed ID: 24602466
    [Abstract] [Full Text] [Related]

  • 62. Standard immunosuppressive therapy of immune-mediated glomerular diseases.
    Pani A.
    Autoimmun Rev; 2013 Jun; 12(8):848-53. PubMed ID: 23219765
    [Abstract] [Full Text] [Related]

  • 63. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
    Siligato R, Cernaro V, Nardi C, De Gregorio F, Gembillo G, Costantino G, Conti G, Buemi M, Santoro D.
    Expert Opin Investig Drugs; 2018 Nov; 27(11):839-879. PubMed ID: 30360670
    [Abstract] [Full Text] [Related]

  • 64. [T-cell lymphoma under immunosuppressive treatment in minimal change glomerulopathy with nephrotic syndrome].
    Späth M, Schollmeyer P.
    Dtsch Med Wochenschr; 1995 Aug 25; 120(34-35):1161-4. PubMed ID: 7656849
    [Abstract] [Full Text] [Related]

  • 65. [The clinico-morphological characteristics and treatment of minimal-change glomerulonephritis and focal-segmental glomerulosclerosis-hyalinosis].
    Diadyk AI, Vasilenko IV, Khomenko MV, Shpilevaia NI, Iarovaia NF, Malovichko IS.
    Lik Sprava; 1995 Aug 25; (9-12):75-8. PubMed ID: 8983800
    [Abstract] [Full Text] [Related]

  • 66. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults.
    Braun N, Schmutzler F, Lange C, Perna A, Remuzzi G, Risler T, Willis NS.
    Cochrane Database Syst Rev; 2008 Jul 16; 2008(3):CD003233. PubMed ID: 18646090
    [Abstract] [Full Text] [Related]

  • 67. The treatment of minimal change disease in adults.
    Hogan J, Radhakrishnan J.
    J Am Soc Nephrol; 2013 Apr 16; 24(5):702-11. PubMed ID: 23431071
    [Abstract] [Full Text] [Related]

  • 68. [Drug treatment of chronic glomerulonephritis: pro].
    Kühn K, Brodehl J, Koch KM, Helmchen U.
    Klin Wochenschr; 1985 Sep 16; 63(18):967-77. PubMed ID: 3903340
    [Abstract] [Full Text] [Related]

  • 69. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
    Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Maas R, Mayer G, Moiseev S, Muto M, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Segelmark M, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A, RITERM study group.
    Autoimmun Rev; 2020 Nov 16; 19(11):102671. PubMed ID: 32942039
    [Abstract] [Full Text] [Related]

  • 70. [Indications for cyclosporin in the treatment of idiopathic nephrotic syndrome in adults].
    Zietse R, Weimar W.
    Ned Tijdschr Geneeskd; 1992 Sep 05; 136(36):1749-53. PubMed ID: 1407123
    [No Abstract] [Full Text] [Related]

  • 71. Immunosuppressive therapy in primary glomerulonephritis (pros).
    Ponticelli C, Banfi G, Imbasciati E, Tarantino A.
    Contrib Nephrol; 1982 Sep 05; (34):33-54. PubMed ID: 6293765
    [No Abstract] [Full Text] [Related]

  • 72. A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING).
    C Willcocks L, Qian W, Cader R, Gatley K, Siddiqui H, Tabebisong E, Champion K, Kronbichler A, Lightstone L, Jayne D, Wilson E, Griffith M.
    BMC Nephrol; 2024 Aug 07; 25(1):253. PubMed ID: 39112932
    [Abstract] [Full Text] [Related]

  • 73. [Late results and prognosis in glomerulonephritis. II. Prognosis in specific forms of glomerulopathies].
    Hruby Z.
    Przegl Lek; 1992 Aug 07; 49(1-2):28-30. PubMed ID: 1455001
    [No Abstract] [Full Text] [Related]

  • 74. [Remission of nephrotic syndrome in patients treated with corticosteroids and other immunosuppressive agents].
    Resić H.
    Med Arh; 2002 Aug 07; 56(2):85-8. PubMed ID: 12014102
    [Abstract] [Full Text] [Related]

  • 75. Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study.
    Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Fukami K, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Yoshio T, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y.
    Clin Exp Nephrol; 2018 Dec 07; 22(6):1266-1280. PubMed ID: 29679356
    [Abstract] [Full Text] [Related]

  • 76. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N.
    BMC Nephrol; 2020 Apr 15; 21(1):134. PubMed ID: 32293308
    [Abstract] [Full Text] [Related]

  • 77. [Cyclosporine and idiopathic extramembranous glomerulopathy. Hypothesis, facts and questions in 1992].
    Rostoker G.
    Nephrologie; 1992 Apr 15; 13(5):207-13. PubMed ID: 1470295
    [Abstract] [Full Text] [Related]

  • 78. Cyclosporin A in steroid-sensitive nephrotic syndrome with frequent relapses.
    Chan MK, Cheng IK.
    Postgrad Med J; 1987 Sep 15; 63(743):757-9. PubMed ID: 3444800
    [Abstract] [Full Text] [Related]

  • 79. Clinicopathologic correlation and outcome of C1q nephropathy.
    Hisano S, Fukuma Y, Segawa Y, Niimi K, Kaku Y, Hatae K, Saitoh T, Takeshita M, Iwasaki H.
    Clin J Am Soc Nephrol; 2008 Nov 15; 3(6):1637-43. PubMed ID: 18650410
    [Abstract] [Full Text] [Related]

  • 80. Immunosuppressive treatment in the prevention of renal failure in primary glomerular diseases.
    Glassock RJ.
    Clin Exp Dial Apheresis; 1981 Nov 15; 5(1-2):21-46. PubMed ID: 7037247
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.